Mind Medicine (MindMed) Inc. Completes $19.5 Million Bought Deal Private Placement

March 08, 2021

Mind Medicine (MindMed) Inc., a psychedelic medicine biotech company that discovers, develops and deploys psychedelic inspired medicines and experiential therapies to address addiction and mental illness, completed a bought deal private placement offering of 6,000,000 units for aggregate gross proceeds of $19,500,000. The offering was conducted by Canaccord Genuity Corp., as underwriter.

Wildeboer Dellelce LLP acted for MindMed in connection with the offering with a team comprising Perry Dellelce, Peter Volk, Rebecca Cochrane, Sarim Ali and Katie Drury (corporate/securities).